10-Q: Organovo Holdings Reports Q3 2025 Results, Faces Going Concern Uncertainty
Sentiment:
Quarterly Report (Form 10-Q)
Organovo Holdings reports Q3 2025 financial results, highlighting ongoing efforts in FXR314 development and 3D tissue modeling, while acknowledging substantial doubt about its ability to continue as a going concern.
Capital raiseThe company is seeking additional funding through debt or equity financings.The company has a shelf registration statement on Form S-3 to register $150.0 million of securities.The company may offer shares of common stock and warrants to purchase shares of common stock in a potential best efforts offering.
Worse than expectedThe company's financial results show a net loss and negative cash flow from operations.The company acknowledges substantial doubt about its ability to continue as a going concern.
Summary
- Organovo Holdings, a clinical stage biotechnology company, is focused on developing FXR314 for inflammatory bowel disease (IBD).
- The company plans to start a Phase 2a clinical trial in ulcerative colitis (UC) in calendar year 2025.
- Organovo is also building high fidelity, 3D tissues that mimic human disease for drug discovery.
- Mosaic Cell Sciences division ended commercial sales operations in Q3 2025, transferring remaining inventory to R&D.
- The company had cash and cash equivalents of approximately $1.2 million and an accumulated deficit of approximately $349.0 million as of December 31, 2024.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company is seeking additional funding through debt or equity financings.
- Total revenue for the three months ended December 31, 2024, was $24,000, consisting of $15,000 in royalty revenue and $9,000 in product revenue.
- Net loss for the three months ended December 31, 2024, was $3.447 million, or $0.19 per share.
- Total revenue for the nine months ended December 31, 2024, was $93,000, consisting of $68,000 in royalty revenue and $25,000 in product revenue.
- Net loss for the nine months ended December 31, 2024, was $9.340 million, or $0.55 per share.
Sentiment
Score: 3
Explanation: The document presents a mixed picture. While the company is making progress in its research and development efforts, the financial results are weak, and there is substantial doubt about its ability to continue as a going concern. The need for additional funding and the Nasdaq delisting notice add to the negative sentiment.
Positives
- The company is advancing FXR314 in IBD, with plans to initiate a Phase 2a clinical trial in UC in 2025.
- Organovo is developing 3D human tissues for drug discovery, which could lead to new therapeutic targets.
- The company has FDA clinical trial authorization for a Phase 2 trial in UC.
- The company released Phase 2 data for FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH) in April 2024 that is supportive of ongoing development.
Negatives
- The company had negative cash flows from operations of approximately $7.4 million during the nine months ended December 31, 2024.
- The company acknowledges substantial doubt about its ability to continue as a going concern.
- Mosaic Cell Sciences division ended commercial sales operations in Q3 2025.
- The company is seeking additional funding through debt or equity financings, which could dilute existing shareholders.
- The company received a notice from Nasdaq regarding non-compliance with minimum bid price requirements.
Risks
- The company's ability to continue as a going concern is dependent on obtaining additional financing.
- Clinical drug development is a lengthy and expensive process with uncertain outcomes.
- The company's success depends on establishing strategic relationships.
- The company may face intense competition in its drug discovery efforts.
- The company may be involved in lawsuits or other proceedings to protect or enforce its patents.
- The company could fail to maintain the listing of its common stock on the Nasdaq Capital Market.
- The company may experience conflicts of interest with Viscient Biosciences, Inc.
Future Outlook
The company plans to advance the clinical drug development of FXR314 and its 3D models for target discovery and drug development, focusing on IBD and broadening into additional therapeutic areas over time. The company expects its total operating expense for the fiscal year ending March 31, 2025 to be between $12.0 million and $14.0 million.
Industry Context
The biotechnology and pharmaceutical industry is subject to intense competition and rapid technological change. Organovo is focusing on FXR314 and 3D tissue modeling, which are areas of active research and development. The company's success will depend on its ability to differentiate itself from competitors and establish strategic relationships.
Comparison to Industry Standards
- It is difficult to compare Organovo's results directly to industry standards due to its unique focus on 3D tissue modeling and its early stage of development.
- Comparable companies in the regenerative medicine and drug discovery space include those focused on 3D bioprinting, such as BICO Group AB, and those developing FXR agonists for IBD, such as CymaBay Therapeutics (acquired by Gilead).
- However, Organovo's financial metrics and progress should be evaluated in the context of its specific technology and development pipeline.
- The company's cash position and burn rate are critical factors to consider in assessing its ability to execute its strategy.
Legal Proceedings
- H.C. Wainwright & Co., LLC filed a complaint against the company alleging breach of contract.
Related Party Transactions
- The company has an intercompany agreement with Viscient Biosciences, Inc., and incurred $118,000 of toxicity testing services from Viscient for the nine months ended December 31, 2024.
Stakeholder Impact
- Shareholders may experience dilution due to future equity offerings.
- Employees face uncertainty due to the company's going concern status.
- Customers and partners may be affected by the company's financial instability.
Next Steps
- The company plans to start a Phase 2a clinical trial in UC in calendar year 2025.
- The company intends to present its plan to the Nasdaq Hearings Panel on February 27, 2025.
- The company intends to monitor the closing bid price of its common stock and consider available options to regain compliance with Nasdaq listing rules.
Key Dates
| Date | Description |
|---|---|
| 2009-03-01 | Date of license agreement with the Curators of the University of Missouri |
| 2011-05-01 | Date of license agreement with Clemson University Research Foundation |
| 2018-03-16 | Date of Sales Agreement with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC |
| 2020-08-25 | Date of Consulting Agreement by and between Company and Danforth Advisors, LLC |
| 2020-11-23 | Date of lease agreement for San Diego Permanent Lease |
| 2020-12-28 | Date of intercompany agreement with Viscient Biosciences |
| 2021-01-29 | Effective date of shelf registration statement on Form S-3 (File No. 333-252224) |
| 2021-11-17 | Date of amendment to San Diego Permanent Lease |
| 2021-12-17 | Commencement date of the Permanent Lease |
| 2022-02-22 | Date of settlement and patent license agreement with BICO Group AB |
| 2022-07-25 | Date of Equity Incentive Plan Two Thousand Twenty Two Member |
| 2022-10-12 | Date of approval of the 2022 Equity Incentive Plan |
| 2022-12-05 | Date of amendment to license agreement with the University of Missouri |
| 2023-07-13 | Effective date of Amended and Restated Bylaws of Organovo Holdings, Inc. |
| 2023-10-31 | Date of stockholder approval of the 2023 Employee Stock Purchase Plan |
| 2024-01-26 | Date of filing of new shelf registration statement on Form S-3 (File No. 333-276722) |
| 2024-02-08 | Effective date of the 2024 Shelf registration statement |
| 2024-02-2024 | Formation of Mosaic Cell Sciences division |
| 2024-03-01 | Commencement of initial offering under the 2023 ESPP |
| 2024-05-08 | Pricing of best efforts public offering |
| 2024-05-13 | Closing of the public offering |
| 2024-07-18 | Receipt of Nasdaq minimum bid price deficiency notice |
| 2024-08-05 | Grant of stock options to Executive Chairman |
| 2024-08-27 | H.C. Wainwright & Co., LLC filed a complaint against the Company |
| 2024-09-01 | Date of Insurance Premium Financing Liability Member |
| 2024-10-18 | The Company filed an answer to the complaint from H.C. Wainwright & Co., LLC |
| 2024-10-25 | Filing of registration statement on Form S-1 for a potential best efforts offering |
| 2024-11-20 | Stockholder approval of amendment and restatement of the 2022 Plan |
| 2024-12-30 | Date of Amendment No. 6 to the Consulting Agreement, dated December 30, 2024 by and between Company and Danforth Advisors, LLC |
| 2025-01-14 | Initial deadline to regain compliance with Nasdaq minimum bid price rule |
| 2025-01-16 | Receipt of Nasdaq delisting notice |
| 2025-02-19 | Date of this report |
| 2025-02-27 | Hearing with Nasdaq Hearings Panel |
| 2025 | Planned start of Phase 2a clinical trial in UC |
| 2025-07-15 | Potential further extension deadline from Nasdaq Hearings Panel |
Keywords
FXR314, inflammatory bowel disease, ulcerative colitis, 3D tissue modeling, drug discovery, clinical trial, Organovo, biotechnology, financing, Nasdaq
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.